Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101247 | 0.69 | MEN1 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19473680 | 0.69 | MEN1 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19976026 | 0.69 | — | — | |
| SCHEMBL1106444 | 0.67 | — | — | |
| SCHEMBL20133824 | 0.67 | MEN1 (0.33) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL13910253 | 0.67 | MEN1 (0.32) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL5543091 | 0.67 | MEN1 (0.32) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19091449 | 0.65 | MEN1 (0.34) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL19353710 | 0.65 | MEN1 (0.34) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL16944043 | 0.65 | ALDH1A1 (0.39) | MEN1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | MEN1 1222/4885CYP3A4 3347/4885CYP2C9 3854/4885 |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | TDP1, TOP1, TOP2A | MEN1 3797/4885CYP3A4 1442/4885CYP2C9 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.